Content deleted Content added
Citation bot (talk | contribs) Altered pages. Add: doi-access, page. Removed parameters. Formatted dashes. | Use this bot. Report bugs. | Suggested by Boghog | #UCB_webform |
→PACIFIC: | Altered journal. | Use this tool. Report bugs. | #UCB_Gadget |
||
Line 100:
==== PACIFIC ====
In November 2017, the double-blinded phase III AstraZeneca PACIFIC clinical trial demonstrated the efficacy of durvalumab in the treatment of stage III [[non-small cell lung cancer]].<ref>{{cite web|url=https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-presents-superior-progression-free-survival-for-imfinzi-in-the-pacific-trial-of-patients-with-locally-advanced-unresectable-lung-cancer-at-esmo-2017-congress-08092017.html|title=AstraZeneca presents superior progression-free survival for Imfinzi in the PACIFIC trial of patients with locally-advanced unresectable lung cancer at ESMO 2017 Congress|date=Sep 2017|website=www.astrazeneca.com|access-date=9 December 2017|archive-date=28 August 2021|archive-url=https://web.archive.org/web/20210828070035/https://www.astrazeneca.com/media-centre/press-releases/2017/astrazeneca-presents-superior-progression-free-survival-for-imfinzi-in-the-pacific-trial-of-patients-with-locally-advanced-unresectable-lung-cancer-at-esmo-2017-congress-08092017.html|url-status=live}}</ref> 709 participants with stage III NSCLC who did not have disease progression after two or more cycles of a platinum-based chemotherapy were randomly assigned to receive durvalumab or a placebo as consolidation therapy for their lung cancer. Durvalumab increased the median progression-free survival from 5.6 months (placebo) to 16.8 months (durvalumab); the 12 month progression-free survival rate was increased from 35.3% (placebo) to 55.9% (durvalumab), and the 18 month progression-free survival rate was increased from 27.0% (placebo) to 44.2% (durvalumab).<ref name=":0" /> The median time to death or distant metastases was also increased from 14.6 months (placebo) to 23.2 months (durvalumab). Extreme side effects were also increased from 26.1% of participants (placebo) to 29.9% of participants (durvalumab).<ref>{{cite journal | vauthors = Fitzpatrick O, Naidoo J | title = Immunotherapy for Stage III NSCLC: Durvalumab and Beyond | journal = Lung Cancer: Targets and Therapy| volume = 12 | pages = 123–131 | date = 2 November 2021 | pmid = 34754256 | pmc = 8572112 | doi = 10.2147/LCTT.S305466 | doi-access = free }}</ref>
==== CASPIAN ====
| |||